Health and Me

Itisha Arya

Trump Strikes Agreement To Cut Costs of Popular Weight Loss Drugs: All You Need to Know

TRUMP ANNOUNCEMENT TODAY

<strong><span rel="noindex">Trumprx</span>:</strong> President <span>Donald Trump</span> on Thursday unveiled agreements with <span>Eli Lilly</span> and <span>Novo Nordisk</span> aimed at cutting the prices of some of their obesity medications, including upcoming pills. The move is designed to make these expensive, blockbuster treatments more accessible to Americans.

<h2><span rel="noindex">Trump Announcement Today</span>: GLP-1 Drugs to Become Affordable for Medicare and Medicaid Beneficiaries</h2>

The deals will reduce costs for GLP-1 drugs for Medicare and Medicaid recipients starting in 2026. The <span>Trump</span> administration also plans to sell the medications directly to consumers at a discount via a new website, TrumpRx.gov, launching in January. For the first time, Medicare will cover obesity treatments, which could encourage private insurers to follow suit. Certain Medicare patients will pay just $50 per month for all approved GLP-1 therapies, including those for diabetes and obesity, as per USA Today.

Also Read: <a href="https://www.healthandme.com/health-news/trumprx-will-trumps-new-website-make-prescription-drugs-more-affordable-article-153112974" data-type="tilCustomLink" target="_blank">TrumpRx: Will Trump’s New Website Make Prescription Drugs More Affordable?</a>

<h2>Trumprx: Wegovy, <span rel="noindex">Zepbound</span>, and Upcoming Pills Set for Price Cuts</h2>

Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approval, will cost $145 per month for those using Medicare, Medicaid, or TrumpRx. Novo Nordisk’s oral version of Wegovy may enter the market by year-end, while Eli Lilly’s pill, orforglipron, could launch next year. Existing injections, such as Wegovy and Zepbound, will be available at $350 per month on TrumpRx, trending down to $245 per month over two years, as per NBC News.

Trump highlighted that these drugs have rarely been covered by Medicaid and were previously not covered by Medicare for weight loss. “They’ve often cost consumers more than $1,000 per month… That ends starting today,” he said.

<h2><span rel="noindex">Trump Announcement</span>: Most Favoured Nation Policy Expands Access</h2>

The announcements are part of the Trump administration’s ongoing push to tie U.S. drug prices to the lowest international costs under the most favored nation policy. Trump has previously reached similar deals with Pfizer, AstraZeneca, and EMD Serono.

HHS Secretary Robert F. Kennedy Jr. said this move will have a “dramatic effect on human health,” noting that all Americans, including those not on Medicaid or Medicare, will benefit from lower GLP-1 drug prices.

Also Read: <a href="https://www.healthandme.com/health-news/trumprx-lowered-prices-of-popular-weight-loss-drugs-what-more-does-trumps-new-medical-website-offer-article-153113373" data-type="tilCustomLink" target="_blank">TrumpRx Lowered Prices Of Popular Weight Loss Drugs; What More Does Trump's New Medical Website Offer?</a>

<h2>Eligibility and Coverage Under Medicare</h2>

<ul><li>Medicare coverage will prioritize three groups:</li><li>Overweight patients (BMI &gt;27) with prediabetes or cardiovascular disease.</li><li>People with obesity (BMI &gt;30) and uncontrolled hypertension, kidney disease, or heart failure.</li><li>Individuals with severe obesity (BMI &gt;35).</li></ul>

About 10% of Medicare beneficiaries are expected to qualify for GLP-1 therapy for obesity, cardiovascular, and metabolic benefits.

<h2>Eli Lilly and Novo Nordisk Commit To Expanded Discounts</h2>

Eli Lilly and Novo Nordisk also agreed to extend lower government pricing to all 50 Medicaid programs, provide most favored nation pricing on new medicines, and offer similar discounts on their existing drugs via TrumpRx.

Eli Lilly will additionally reduce prices on its direct-to-consumer platform, LillyDirect, where Zepbound will be available starting at $299 per month for the lowest dose. Eli Lilly’s upcoming pill will start at $149 per month.

<h2>Background on Obesity Drug Coverage</h2>

Previous efforts to cover obesity drugs under Medicare, including a proposal by former President Joe Biden, were not finalized due to costs and controversy. Health experts argue that broader access could reduce long-term expenses related to obesity-related conditions.

Semaglutide is also slated for Medicare price negotiations under the Inflation Reduction Act, while tirzepatide, the active ingredient in Zepbound, may not be part of such negotiations until the decade’s end.

Health Conditions A-Z

health

trump-announcement-today

trump

donald trump

trumprx

trump rx

trump announcement today

eli lilly

novo nordisk

zepbound

trump announcement

shift-to-plant-based-proteins-low-fat-dairy-to-boost-heart-health-american-heart-association

Shift to Plant-Based Proteins, Low-Fat Dairy To Boost Heart Health: American Heart Association

ozempic-and-wegovy-prices-slashed-again-in-india-to-counter-cheaper-generics

Ozempic And Wegovy Prices Slashed Again In India To Counter Cheaper Generics

breast-conservation-surgery-vs-mastectomy-what-surgeons-recommend-today

Breast Conservation Surgery vs Mastectomy: What Surgeons Recommend Today

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Trumprx: President Donald Trump on Thursday unveiled agreements with Eli Lilly and Novo Nordisk aimed at cutting the prices of some of their obesity medications, including upcoming pills. The move is designed to make these expensive, blockbuster treatments more accessible to Americans.Trump Announcement Today: GLP-1 Drugs to Become Affordable for Medicare and Medicaid BeneficiariesThe deals will reduce costs for GLP-1 drugs for Medicare and Medicaid recipients starting in 2026. The Trump administration also plans to sell the medications directly to consumers at a discount via a new website, TrumpRx.gov, launching in January. For the first time, Medicare will cover obesity treatments, which could encourage private insurers to follow suit. Certain Medicare patients will pay just $50 per month for all approved GLP-1 therapies, including those for diabetes and obesity, as per USA Today.Also Read: TrumpRx: Will Trump’s New Website Make Prescription Drugs More Affordable?Trumprx: Wegovy, Zepbound, and Upcoming Pills Set for Price CutsStarting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approval, will cost $145 per month for those using Medicare, Medicaid, or TrumpRx. Novo Nordisk’s oral version of Wegovy may enter the market by year-end, while Eli Lilly’s pill, orforglipron, could launch next year. Existing injections, such as Wegovy and Zepbound, will be available at $350 per month on TrumpRx, trending down to $245 per month over two years, as per NBC News.Trump highlighted that these drugs have rarely been covered by Medicaid and were previously not covered by Medicare for weight loss. “They’ve often cost consumers more than $1,000 per month… That ends starting today,” he said.Trump Announcement: Most Favoured Nation Policy Expands AccessThe announcements are part of the Trump administration’s ongoing push to tie U.S. drug prices to the lowest international costs under the most favored nation policy. Trump has previously reached similar deals with Pfizer, AstraZeneca, and EMD Serono.HHS Secretary Robert F. Kennedy Jr. said this move will have a “dramatic effect on human health,” noting that all Americans, including those not on Medicaid or Medicare, will benefit from lower GLP-1 drug prices.Also Read: TrumpRx Lowered Prices Of Popular Weight Loss Drugs; What More Does Trump's New Medical Website Offer?Eligibility and Coverage Under MedicareMedicare coverage will prioritize three groups:Overweight patients (BMI >27) with prediabetes or cardiovascular disease.People with obesity (BMI >30) and uncontrolled hypertension, kidney disease, or heart failure.Individuals with severe obesity (BMI >35).About 10% of Medicare beneficiaries are expected to qualify for GLP-1 therapy for obesity, cardiovascular, and metabolic benefits.Eli Lilly and Novo Nordisk Commit To Expanded DiscountsEli Lilly and Novo Nordisk also agreed to extend lower government pricing to all 50 Medicaid programs, provide most favored nation pricing on new medicines, and offer similar discounts on their existing drugs via TrumpRx.Eli Lilly will additionally reduce prices on its direct-to-consumer platform, LillyDirect, where Zepbound will be available starting at $299 per month for the lowest dose. Eli Lilly’s upcoming pill will start at $149 per month.Background on Obesity Drug CoveragePrevious efforts to cover obesity drugs under Medicare, including a proposal by former President Joe Biden, were not finalized due to costs and controversy. Health experts argue that broader access could reduce long-term expenses related to obesity-related conditions.Semaglutide is also slated for Medicare price negotiations under the Inflation Reduction Act, while tirzepatide, the active ingredient in Zepbound, may not be part of such negotiations until the decade’s end.